Immuno-Oncology 360° Agenda 2026 Page 2

Explore By Subject Area

Day Two: Wednesday, February 11, 2026

List/Print View

Showing Events in 1 Track from 07:45am to 08:45am

Morning Remarks
Grand Ballroom

7:45AM - 8:15AM

Registration & 1:1 Meetings

8:15AM - 8:20AM

Co-Chairs’ Welcome

Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine

Naiyer Rizvi, MD, CMO, Synthekine

8:20AM - 8:45AM

Fireside Keynote: What’s Next in Immuno-Oncology - A Visionary Conversation with Dr. Ira Mellman

Fireside Guest:

Ira Mellman, PhD, President of Research, Parker Institute for Cancer Immunotherapy (PICI)

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Showing Events in 1 Track from 08:45am to 09:25am

State of the IO Market, Investments and Deals Plenary
Grand Ballroom

8:45AM - 9:05AM

IO Capital Markets Outlook for Biotechs & IO

Lorenzo Paoletti, MBA, Managing Director, Biopharma Investment Banking, Bank of America

9:05AM - 9:25AM

M&A Strategies in Biotech: Navigating the Path to Acquisition

Rick Aldridge, MBChB, Managing Director, Healthcare Investment Banking, BMO Capital Markets

Showing Events in 1 Track from 09:25am to 10:05am

Morning IO360º Breakfast, Networking, Exhibits & 1:1 Partnering Meetings
Networking & Exhibits: Grand Ballroom Foyer / 1:1 Partnering Meetings: Back Bay AB

9:25AM - 10:05AM

Morning Networking Break

Showing Events in 1 Track from 10:05am to 10:50am

IO360° Biotech Showcase

10:05AM - 10:50AM

IO360° Biotech Showcase

Participating Companies:

Showing Events in 2 Tracks from 10:05am to 10:49am

Track 1: IO360° Biotech Showcase A
Grand Ballroom

Track Chair:

Graig C. Suvannavejh, PhD, Managing Director, Equity Research Biopharmaceuticals & Biotechnology, Mizuho Securities USA

10:05AM - 10:13AM

7 Hills Pharma Inc.

Upendra Marathi, PhD, MBA, CEO, 7 Hills Pharma Inc.

10:14AM - 10:22AM

TATUM Bioscience

Jean-Francois Millau, PhD, CEO & Co-Founder, TATUM Biosciences

10:23AM - 10:31AM

William Jia, PhD, CSO & Co-founder, Virogin Biotech

10:32AM - 10:40AM

Tarek Ali Zaki, CEO & Co-Founder, OncoPrecision

10:41AM - 10:49AM

Angelica Loskog, PhD, CEO/CSO, Lokon Pharma

Track 2: IO360° Biotech Showcase B
Constitution Ballroom AB

Track Chair:

Leon 'Jun' Tang, PhD, Founding Partner / Co-Founder, InScienceWeTrust BioAdvisory / InScienceWeTrust Community

10:05AM - 10:13AM

Abalos Therapeutics

Gerben Moolhuizen, CEO, Abalos Therapeutics

10:14AM - 10:22AM

Shawn Davis, PhD, CEO, Liberate Bio

10:23AM - 10:31AM

Stingray Therapeutics, Inc

Jonathan Northrup, MBA, Co-Founder & CEO, Stingray Therapeutics, Inc.

10:32AM - 10:40AM

Matteo Stoppato, PhD, Senior Director, Head of R&D, Syenex

10:41AM - 10:49AM

Filippo Petti, CEO, Leucid Bio

Showing Events in 1 Track from 10:50am to 10:55am

5 Minute Health Break

10:50AM - 10:55AM

5 Minute Health Break

Showing Events in 1 Track from 10:55am to 12:15pm

State of the IO Market, Investments and Deals Plenary (Continued)
Grand Ballroom

Track Chair:

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

10:55AM - 11:35AM

What Makes a Smart Deal in IO? Navigating Capital, Competition, and Global Innovation

Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer

Jeffrey M. Bockman, PhD, Expert Advisor and EVP, Oncology, Lumanity

Deepa Pakianathan, PhD, Managing Partner and CEO/Co-Founder, Delphi Ventures / Stealth Oncology Company

Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca

Markus Werner, PhD, Head, Search & Evaluation, Oncology, Novartis

Evan Zisholtz, JD, VP, Global Business Development, Immunai

11:35AM - 12:15PM

IO Investment Trends: What’s Driving Capital in 2026?

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Reni Benjamin, PhD, Managing Director, Citizens Capital Markets and Advisory

Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments

Cailin McGurk, Managing Director, Healthcare Investment Banking, Morgan Stanley

I-hung Shih, PhD, MBA, Managing Director & Portfolio Manager, Eventide Asset Management

Showing Events in 1 Track from 12:15pm to 01:15pm

Lunch
Networking & Exhibits: Grand Ballroom Foyer / 1:1 Partnering Meetings: Back Bay AB

12:15PM - 1:15PM

Lunch & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 01:20pm to 03:20pm

TRACK 1: Breakthroughs in Translational Science, Imaging & Biomarkers
Grand Ballroom

Track Chair:

Marisa Dolled-Filhart, PhD, Global Team Lead, Early Oncology; Asset and Portfolio Management, Daiichi Sankyo US

1:20PM - 1:40PM

VIP Talk: Targeting Myeloid Cells for Therapeutic Enhancement

Miriam Merad, MD, PhD, Chair, Department of Immunology and Immunotherapy, Director, Marc and Jennifer Lipschultz Precision Immunology Institute, Director, Mount Sinai Human Immune Monitoring Center, Mount Sinai School of Medicine

1:40PM - 2:00PM

18F CD8-PET Imaging: Transforming IO Development and Patient Care

Stephane Champiat, MD, PhD, Medical Oncologist, The University of Texas MD Anderson Cancer Center

Kristen Wangerin, PhD, Senior Imaging Technology Leader, Pharmaceutical Diagnostics, GE HealthCare

2:00PM - 2:20PM

Engineering the Optimal T Cell Engager: From Molecular Design to Clinical Translation

Julie Bailis, PhD, Vice President, Oncology Research, Amgen

2:20PM - 2:40PM

Leveraging ctDNA MRD to Accelerate Drug Development and Monitor Treatment Response

Dejan Knezevic, PhD, Senior Director, Bio Pharma Business Development, Natera

2:40PM - 3:00PM

Leveraging Synthetic Antigens to Create Universal Immunotherapies for Solid Tumors

Barbra Sasu, PhD, CSO, Dispatch Bio

3:00PM - 3:20PM

First-in-Human Imaging of a Zirconium-89-Labeled Monoclonal Antibody in Small Cell Lung Cancer

Diederik Grootendorst, PhD, Director, Global Oncology Imaging, Bristol Myers Squibb

TRACK 2: IO Cell Therapy Plenary
Constitution Ballroom AB

Track Chair:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

1:20PM - 2:00PM

In Vivo Cell Therapy: Rewriting the Rules of Cell-Based Treatment

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

Gwendolyn Binder, PhD, President, Science & Technology, Cabaletta Bio

Adrian Bot, MD, PhD, Former EVP, R&D and Founding CSO, Capstan Therapeutics

Dong Geng, PhD, SVP, Global EDD and Preclinical Development, Legend Biotech

Jacek Lubelski, PhD, Chief Technology Officer, NanoCell Therapeutics

Philippe Parone, PhD, Head, Cell Therapy In Vivo / CSO, AstraZeneca / EsoBiotec

2:00PM - 2:20PM

Islet Transplantation for Type 1 Diabetes

Fouad Kandeel, MD, PhD, Arthur D Riggs Distinguished Chair in Diabetes and Metabolism Research, Professor and Chair Department of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope

2:20PM - 2:40PM

iPSC Therapy for Parkinson’s

Seth Ettenberg, PhD, President and CEO, BlueRock Therapeutics

2:40PM - 3:20PM

iPSC 2.0: From Promise to Productization

Michael Rice, MS, MBA, Expert Advisor, Senior Vice President, Cell and Gene Therapy, Lumanity

Bobby Goulding, PhD, Director, Corporate Strategy, Fate Therapeutics

Dhavalkumar Patel, MD, PhD, EVP & CSO, Sana Biotechnology

Greg Russotti, PhD, Chief Technology and Manufacturing Officer, Century Therapeutics

Vic Stone, Head of Cell Therapies and Head of Alloy Japan, Alloy Therapeutics

Showing Events in 1 Track from 03:20pm to 04:00pm

Afternoon Networking Break
Networking & Exhibits: Grand Ballroom Foyer / 1:1 Partnering Meetings: Back Bay AB

3:20PM - 4:00PM

Afternoon Networking Break & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 04:00pm to 05:30pm

TRACK 1: Translational Science & Biomarkers – Expanding Therapeutic Horizons
Grand Ballroom

Track Chair:

Paul Noto, PhD, Scientific Director; Precision Medicine Heme and Immuno-Oncology, AbbVie

4:00PM - 4:20PM

From Oncology to Autoimmune Diseases: Expanding the Impact of Plasma-Cell Directed Therapies

Prof Dr Med Ricardo Grieshaber-Bouyer, MHBA, Head of the Clinical Trial Unit; Professor of Clinical Systems Immunology, Department of Internal Medicine 3 – Rheumatology and Immunology;, FAU Erlangen-Nürnberg and University Hospital Erlangen

4:20PM - 4:35PM

Deep-Learning Serial CT Prediction of Survival in Immunotherapy-treated Non-Small Cell Lung Cancer

Petr Jordan, PhD, CTO, Onc.AI

4:35PM - 4:55PM

Targeting Fascin to Disrupt Metastasis and Reinvigorate Anti-Tumor Immunity

Jose Jimeno, MD, PhD, Chief Medical Officer, Novita Pharma

4:55PM - 5:10PM

Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin

Lan Huang, PhD, Chairwoman, CEO & Co-Founder, BeyondSpring Inc.

5:10PM - 5:30PM

Successful Treatment of HPV-associated Recurrent Respiratory Papillomatosis (RRP) with HPV-specific Immunotherapy: Results from a Pivotal Phase 1/2 Clinical Trial

Scott M Norberg, DO, Associate Research Physician, Center for Immuno-Oncology; Head, Solid Tumor Cellular Therapy Group, Center for Cancer Research, National Cancer Institute, National Institute of Health (NIH)

TRACK 2: IO Cell Therapy Plenary
Constitution Ballroom AB

Track Chair:

Kimberly Schluns, PhD, Sr Director, Kite Pharma

4:00PM - 4:35PM

Rebuilding TCR-T Cell Therapy: Novel Targets, Smarter Circuits, and the Road to Universality

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

Reagan Jarvis, PhD, CEO & Scientific Founder, Anocca

Harpreet Singh, PhD, CEO, Immatics

Eric Tran, PhD, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute

Elizabeth Wood, PhD, CEO & Founder, Jura Bio, Inc

4:35PM - 5:10PM

Beyond the Bench: AI Integration Across the Cell Therapy Pipeline

Samik Upadhaya, PhD, Director of Scientific Affairs, Cancer Research Institute

Daniel Baker, PhD, Scientist, June Lab University of Pennsylvania

Marc Lajoie, PhD, Co-founder & CEO, Outpace Bio

Adeeb Rahman, PhD, CTO, Immunai

Elizabeth Wood, PhD, CEO & Founder, Jura Bio, Inc

5:10PM - 5:30PM

The State of TIL Therapy: Innovation, Lessons Learned, and What’s Next

Kimberly Schluns, PhD, Sr Director, Kite Pharma

Fireside Guests:

Igor Bilinsky, PhD, Chief Operating Officer, Iovance Biotherapeutics

Parameswaran Hari, MD, CMO, Obsidian Therapeutics

Anna Truppel-Hartmann, MD, Chief Medical Officer, KSQ Therapeutics

Showing Events in 1 Track from 05:35pm to 06:10pm

IO360° Cancer Immunotherapy Debate
Grand Ballroom

5:35PM - 6:10PM

IO360° Annual Debate: Multifunctional vs. Monospecific Antibodies - Which Defines the Future of IO?

Daniel S Chen, MD, PhD, Founder & CEO, Synthetic Design Lab, Inc

Debate Participants:

Michael Curran, PhD, Professor, Department of Immunology / Founder, MD Anderson Cancer Center / ImmunoGenesis, Inc

Naiyer Rizvi, MD, CMO, Synthekine

Day One

Tuesday, February 10, 2026

Day Three

Thursday, February 12, 2026

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.